Former Chief Financial Officer and Vice President · Spyre Therapeutics, Inc. (SYRE)

Charles York II

A named executive officer of Spyre Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,283,468

Salary $415,000Stock awards $860,415

FY2019: $1,085,136

2nd of 3 named executive officers at Spyre Therapeutics by FY2020 total.

3 named officers on file for Spyre Therapeutics, FY2020

Charles York II’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • SYRE’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Spyre Therapeutics’s whole pay program stands against its peers

  • Spyre Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SYRE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2021 (DEF 14A).

Free

Get Charles York II’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Charles York II compensation by year

Spyre Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Spyre Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020
Salary$325,000$343,000$390,000$415,000
Bonus$130,000$185,000$0$0
Stock awards$660,082$424,842$522,424$860,415
Option awards$0$0$0$0
Non-equity incentive$0$0$165,000$0
Pension and deferred compensation$0$0$0$0
All other$15,707$7,981$7,712$8,053
Total$1,130,789$960,823$1,085,136$1,283,468

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spyre Therapeutics, Inc. DEF 14A filed April 22, 2021, accession 0001564590-21-019953, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Spyre Therapeutics, Inc. filed document, accession 0001564590-21-019953. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2021.

$1.1M
$961K
$1.1M
$1.3M
FY17
FY18
FY19
FY20
SalaryBonusNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,600$83,422—
RSU10,600$83,422—
Option26,863—$6.31
Option99,750—$8.15
Option5,625—$8.03
Option21,200—$8.13
Option47,450—$8.36

Per the Outstanding Equity Awards at Fiscal Year-End table in Spyre Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Spyre Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Anthony QuinnChief Executive Officer$2,909,606
Charles York II · this pageFormer Chief Financial Officer and Vice President$1,283,468
Leslie SloanChief Operating Officer$1,246,319

The full Spyre Therapeutics compensation record

free company brief

This page is one person within Spyre Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Spyre Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spyre Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charles York II's compensation dossier · One-time report. No refunds.